Видео ютуба по тегу Bridgebio Pharma

BridgeBio Pharma #BBIO стоит ли покупать акции компании в 2022 году? Разбор pipeline.
BridgeBio Pharma #BBIO стоит ли покупать акции компании в 2022 году? Разбор pipeline.
BridgeBio Pharma, Inc. BBIO, презентация финансовых результатов за третий квартал 2025 г.
BridgeBio Pharma, Inc. BBIO, презентация финансовых результатов за третий квартал 2025 г.
BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization
BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization
Стоит ли ажиотаж вокруг акций BridgeBio Pharma (BBIO)?
Стоит ли ажиотаж вокруг акций BridgeBio Pharma (BBIO)?
BridgeBio Pharma: My Take on Their Latest Financials
BridgeBio Pharma: My Take on Their Latest Financials
Putting Patients First: BridgeBio Founder & CEO, Neil Kumar, Ph.D. at Milken 2025
Putting Patients First: BridgeBio Founder & CEO, Neil Kumar, Ph.D. at Milken 2025
BridgeBio Pharma stock analysis - would ChatGPT buy or sell today? [May 2025]
BridgeBio Pharma stock analysis - would ChatGPT buy or sell today? [May 2025]
BridgeBio Pharma Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar | Sep 10, 2025
BridgeBio Pharma Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar | Sep 10, 2025
Explore the scientific development of an investigational medicine for ADH1
Explore the scientific development of an investigational medicine for ADH1
Джастин То — генеральный директор QED Therapeutics, компании Bridge Bio — Эпизод 103
Джастин То — генеральный директор QED Therapeutics, компании Bridge Bio — Эпизод 103
How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech
How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech
BBIO BridgeBio Pharma Stock Analysis: Q2 Loss Order Shocks - What's Next? 💥 Predicted Opening Price!
BBIO BridgeBio Pharma Stock Analysis: Q2 Loss Order Shocks - What's Next? 💥 Predicted Opening Price!
Bridgebio shares surge on takeout target hopes
Bridgebio shares surge on takeout target hopes
КРУПНЫЙ ПРОРЫВ: АНАЛИЗ АКЦИЙ BBIO | АКЦИИ BRIDGEBIO PHARMA
КРУПНЫЙ ПРОРЫВ: АНАЛИЗ АКЦИЙ BBIO | АКЦИИ BRIDGEBIO PHARMA
🧬 𝗕𝗥𝗜𝗗𝗚𝗘𝗕𝗜𝗢 𝗣𝗛𝗔𝗥𝗠𝗔 (𝗡𝗔𝗦𝗗𝗔𝗤: 𝗕𝗕𝗜𝗢) | 𝗥𝗔𝗥𝗘 𝗗𝗜𝗦𝗘𝗔𝗦𝗘 𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗟𝗘𝗔𝗗𝗘𝗥
🧬 𝗕𝗥𝗜𝗗𝗚𝗘𝗕𝗜𝗢 𝗣𝗛𝗔𝗥𝗠𝗔 (𝗡𝗔𝗦𝗗𝗔𝗤: 𝗕𝗕𝗜𝗢) | 𝗥𝗔𝗥𝗘 𝗗𝗜𝗦𝗘𝗔𝗦𝗘 𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗟𝗘𝗔𝗗𝗘𝗥
Burjeel Holdings Collaborates With US-based BridgeBio Pharma For 'NADER' Project
Burjeel Holdings Collaborates With US-based BridgeBio Pharma For 'NADER' Project
Meet the PAL Team Director — Heather
Meet the PAL Team Director — Heather
BridgeBio's $300M Royalty Deal: Here's What I'm Really Thinking
BridgeBio's $300M Royalty Deal: Here's What I'm Really Thinking
Bridgebio Genetic HypoPARA & ADH1
Bridgebio Genetic HypoPARA & ADH1